Meeting
2021 Gastrointestinal Cancers Symposium
Population-based, real-world prognostic factors related to survival among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Authors
Kenneth H. Yu
Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, NY
Kenneth H. Yu , Paul Cockrum , Andy Surinach , Shu Wang , Bong Chul Chu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Pancreatic Cancer
Track
Pancreatic Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 389)
DOI
10.1200/JCO.2021.39.3_suppl.389
Abstract #
389
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Real-world study of treatment patterns and outcomes among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in Europe.
First Author: Julien Taieb
Poster
2021 Gastrointestinal Cancers Symposium
Real-world outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma.
First Author: Laura Miotke
Poster
2024 ASCO Annual Meeting
Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM).
First Author: Erica S Tsang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world overall survival and time to next treatment in patients with metastatic pancreatic ductal adenocarcinoma who received FOLFIRINOX and modified FOLFIRINOX in the first line.
First Author: Syvart Dennen